Market Access Summit - Detailed Agenda

Registration and Continental Breakfast

Opening Comments From the Chair

Jeff Graham, Partner, Borden Ladner Gervais

OPENING KEYNOTE PRESENTATION

Public Payers: How government works to accomplish large-scale changes

Ontario has recently seen many changes in the health care industry, from generic pricing reform to the use of PLAs. Balancing the complexities of health care with industry is enormously challenging given the many stakeholders. Hear how:

• To balance industry with public payer goals
• ODB works with elected officials and industry
• Public payers negotiate the bureaucracy

Understand how public payers initiate change, and balance complex priorities

Helen Stevenson, President and CEO, Reformulary Group

PMPRB UPDATE

How the new guidelines are affecting the industry, and what stakeholders can expect in the coming years

It has now been more than a year since the Board's new excessive pricing guidelines have been implemented. Join us as we delve into the recent decisions, and what stakeholders can expect in the future.

• Analyze how the PMPRB's new excessive pricing guidelines are being implemented
• Identify where challenges and opportunities are coming from
• Price review and key trends stemming from the 2010 Annual Report
• Evolving pharmaceutical environment and potential implications

Review the past events and future expectations at the PMPRB

Michelle Boudreau, Executive Director, PMPRB

Networking Break

Interact with conference speakers and fellow attendees.

COMMON DRUG REVIEW UPDATE

Review of the past year and gain insight into the year ahead

There continues to be a great deal of change with CADTH and the CDR. As the CDR evolves, all stakeholders must meet these new challenges. Join us as we unravel the latest developments of the CDR.

• Review the past year, and some recent decisions
• Examine how CDR will evaluate and recommend medications for listing
• Understand how to work with the CDR to improve your listing opportunities

Gain a better understanding of how the CDR is evolving and how you can work with them to meet your goals

George Wyatt, Managing Director, Wyatt Health Management

KEYNOTE PRESENTATION: INTERNATIONAL PRICING

How global pricing and access issues could influence Canadian policy

Canada looks at many countries to gauge how other jurisdictions are dealing with pricing and access. In many cases, changes in international policy can predict changes in Canadian policy and pricing. With this in mind, we look at how international jurisdictions are:

• Amending policy to affect access
• Controlling costs through various strategies
• Working with manufacturers to facilitate best price

Stay up to date on international developments in pricing and access

Nick Bosanquet, Professor of Health Policy, Imperial College, London (UK)

Networking Luncheon

Join the conference speakers and your peers for a relaxing luncheon.

PRIVATE INSURANCE PANEL INTRODUCTION

How is market access and reimbursement changing among private payers?

Because such a large share of the drug spend comes from private plans, private insurers, employers, and benefit consultants are looking to control those costs. Review key changes in the health care landscape, including:

• The influence of employers on drug plans
• Private plan cost drivers and potential market shifts
• How the generic market changes are changing private plans
• How PLA's may be part of the private market as well

Analyze some of the recent developments in private payer plans

Suzanne Lepage, Private Health Plan Strategist, President, Suzanne Lepage Consulting

PRIVATE INSURANCE PANEL DISCUSSION

How private insurance companies are affecting pricing and access

There are many stakeholders affecting access to medications. Employers are looking to their insurers to help them manage their growing drug plan costs. Join us for a frank discussion of how the private payer market is changing, in both the near and long term.

• What new strategies are insurers recommending to employers?
• What cost management tools are they recommending?
• How can manufacturers preserve access?

Gain valuable insight into how private insurance companies are influencing price and access

Shelley Kee, VP, Group Business (Atlantic Canada), Medavie Blue Cross	Joanne Jung, Manager, Pharmacy Services, Pacific Blue Cross
Wayne Millar, AVP, Group Product Development, Sun Life	Moderator: Suzanne Lepage, Private Health Plan Strategist, President, Suzanne Lepage Consulting

PREFERRED PHARMACY NETWORKS

The New Reality: How to respond to cost conscious payers, evolving legislative changes and preferred pharmacy networks

With a greater emphasis on cost cutting, both public and private payers are looking at all options. One option is preferred pharmacy networks, but there are many other factors of influence, including.

• Relevant legal constraints and implications – Competition Act, Drug reform pricing legislation and any other legal considerations
• Regulatory approval processes and challenges for generics
• Potential partnering opportunities
• Various physician loyalty programs and or added-value services targeted to physicians, pharmacists, and/or government

Kevin West, VP Strategic Partnerships and Government Relations, Innomar Strategies

Networking Break

Interact with conference speakers and fellow attendees.

EMPLOYER PANEL

What are plan sponsors thinking and how are they influencing pricing and access?

It is often said that current cost trajectories are unsustainable for private drug benefit plans. With employers paying for 30% of all drugs, they are starting to take notice. The most vulnerable are the small to medium sized companies, but even large companies are looking to control health costs.

• What options are being considered now, in the short term?
• How are employers looking at controlling prices over the long term?
• What are they looking for from manufacturers?

Broaden your understanding of the private payer market

Celine Chiovitti, Director, Pension, Payroll and Employee Benefits, City of Toronto	Satinder Chera, VP Provincial Affairs for Ontario, Canadian Federation of Independent Businesses
Helen Stevenson, President and CEO, Reformulary Group	More to come...

PATIENT ENGAGEMENT

Assessing the current environment and successful strategies for collaborating with patients

Patients are the most affected by access and pricing. Consequently, working with patient groups is important for all parties to maximize access.

• Hear how patient groups interact with government to achieve access
• Identify effective strategies for collaborating with patients
• Dissect which issues patient groups are most interested in

Unravel the current environment and effective strategies for working with patient groups to increase access to therapies

Paulette Eddy, Executive Director, Best Medicines Coalition

Conference adjourns to Day Two

Evening Social Activities

Continue to network with peers and industry leaders while enjoying some of the best Toronto has to offer. Start by joining fellow delegates and speakers for complimentary appetizers at our "exclusive" end-of-day gathering.

Registration and Continental Breakfast

Opening Comments From the Chair

Jeff Graham, Partner, Borden Ladner Gervais

KEYNOTE: COMPARATIVE EFFECTIVENESS RESEARCH (CER)

International perspectives in CER and how new research can affect your role

Delivering efficient, quality, and sustainable health care is leading to more research and focus on evidence-based decision-making. Several countries are reviewing and evaluating their health care technologies. Review how other countries are employing CER.

• Review the motivation for, and why, CER is becoming more important
• Determine how other countries are evaluating medicines and evidence
• Grasp how inroads to CER can provide better and more cost-effective treatments

Improve your understanding of CER in other countries

Anita Burrell, Associate VP, Distinct Project Unit, MS, Sanofi Aventis (US)

CASE STUDY: UNITED KINGDOM COST CONTROLS

How NHS Trusts are controlling costs and what it could mean for Canadian stakeholders

In order to control health care costs, countries are looking at varied ways to cut spending. Often, it is medication that is cut, in part because it takes a large percentage of the health budget. In the UK, Primary Care Trusts (PCT) are doing this through restricting access to certain medications to remain cost effective. Hear how PCTs are:

• Valuing medications and listing them
• Determining which medications will not be covered
• Looking at future use of health care dollars

Hear how NHS Trusts are controlling costs and what it could mean for Canada

David Stout, Director, Primary Care Trust Network

Networking Break

Interact with conference speakers and fellow attendees.

INDUSTRY ROUNDTABLE

The practical implications of the agencies that regulate pricing and listing agreements in Canada

We have heard from the PMPRB and are aware of several international trends. Now, it's time for the industry to dissect the implications. Join our discussion as we consider possible responses to meet new guidelines and global trends.

• What are the most likely challenges and impediments?
• How will PLA's fit into these new challenges?
• How will cancer medications be affected?
• What are the implications for orphan drugs?

Join in as we dissect national and international pricing and listing agreements

Karen Netherton, VP Policy and Reimbursement, Novartis	Moderator: Neil Palmer, President and Principal Consultant, PDCI
Alain Boisvert, VP for Market Access, Policy and Communications at Bristol-Myers Squibb	More to come...

CASE STUDY: PATENT CLIFF

Dealing with the Patent Cliff: Better ways of collaborating with retail pharmacy to maintain access

Each manufacturer is struggling with patent loss, and the possibility of generic substitution. Although patents cannot be extended, access can still be maintained with some innovative strategies. As you prepare for the loss of exclusivity, what can you do?

• Innovate your approach to building and maintaining brand loyalty
• Partner with a retail pharmacy, and create a win-win?
• Hear case studies from Quebec and Ontario

Learn how you can respond to the patent cliff through innovative ways of collaborating with retail pharmacies

Moderator: Dimitris Polygenis, VP Specialty McKesson Canada

More to come...

PERSONALIZED MEDICINE

How personalized medicine can impact the industry

Advances in genetic testing have made it possible, in some cases, to deploy personalized medical care, with some promising and cost-effective results.

• What are the current challenges facing the industry?
• How will personalized medicine impact price – and outcomes?

Be aware of how personalized medicine is being employed, and how it affects price and outcomes

Clarissa Desjardins, Chief Executive Officer, CEPMED

Networking Luncheon

Join the conference speakers and your peers for a relaxing luncheon.

How Cancer Care Ontario’s new evidence-building program is being implemented and what it means for patient access

Due to recent advancements in diagnostics, it is becoming possible to find smaller and smaller tumors. This has lead CCO to look at when certain medications are covered. This new program will have important implications for access. Hear how CCO is:

• Rolling out the program
• Evaluating and monitoring outcomes
• Working with patients and manufactures to facilitate better access

Gather insight into CCO’s newest access program

Scott Gavura, Director, Provincial Drug Reimbursement Programs, Cancer Care Ontario

BIOLOGICS AND ADHERENCE

Enhanced strategies for delivering better patient adherence, increased compliance, and more accurate prescribing data

A lack of compliance and adherence can have detrimental effects to all parties. From Skipping doses, to improper administration of auto injectables, lack of adherence and compliance can hinder patient outcomes, but it can also produce skewed data, resulting in lower prescriptions and increased misunderstandings about the benefits of biologics. Overcoming these challenges requires a multi-pronged approach. Some take away strategies will include:

• Countering current patient adherence and compliance trends
• Delivering cost-effective adherence on biologic response modifiers
• Building strong relationships between pharmaceutical companies, pharmacies, insurance companies (private and public) and prescribing physicians/specialists

Take back practical solutions to ensuring patients remain compliant with their course of treatment

Andrew J. Leyva, Reimbursement Manager, Bayshore Specialty Rx, Patient Support Services

Influencing access: How much influence should patients have in determining access and costs

Patients (consumers) are more aware of available medications, and are not shy about asking for a specific medication. Those with plans will choose a higher cost medication, and physicians will usually comply with a patient's wishes. However, is this the best way to go? Join us as we delve into the present and future of consumerism in the medical market place.

• Should consumers be free to design their own plan?
• What is the role of the physician when prescribing patient directed medications?
• Should coverage or desired outcome influence prescribing behaviour?

Engage the panel in a lively discussion around consumer based access models

Networking Break

Interact with conference speakers and fellow attendees.

LITIGATION BEFORE AND AGAINST THE PMPRB: 2011 UPDATE

Celgene vs. PMPRB: What the recent Supreme Court decision means for the industry

On January 20, 2011, the Supreme Court of Canada released its much-anticipated decision in Celgene. To the surprise of many interested observers, the Court affirmed the PMPRB's jurisdiction over a purchase and sale of Thalomid in New Jersey, pursuant to Health Canada's Special Access Programme ("SAP"). The Court's broad interpretation of the PMPRB's jurisdiction over sales "in any market in Canada" has potentially far reaching consequences. This year's litigation update will address:

• Putting the Celgene decision in the context: How does it fit with past PMPRB litigation, and what can the industry expect going forward?
• The reach of the PMPRB: Does the Board have jurisdictional carte blanche, or are there limits?
• Other cases before the Board and the Courts
• The next big challenge: PMPRB rule-making

Understand how the recent Supreme Court decision will affect pricing in Canada

Doug Worndl, Partner, Siskinds

SUBSEQUENT ENTRY BIOLOGICS

How is new legislation in the US affecting Canadian regulations?

The US Congress passed legislation in 2010 that would address price and innovation for biologics, including so called biosimilars (SEBs). Currently, the FDA is studying how to interpret this legislation, but the US model does raise several questions for the Canadian Biologics industry.

• What are the specific US regulations that could influence Canadian regulations?
• Where are the main concerns here in Canada?
• How will/could they be addressed given recent US developments?

Lesley Rapaport, President, LRR Patent Law

Conference adjourns